期刊
ACTA HAEMATOLOGICA
卷 -, 期 -, 页码 -出版社
KARGER
DOI: 10.1159/000510281
关键词
Myeloproliferative neoplasm; t(8; 9)(p22; p24); JAK2 kinase inhibitor; Ruxolitinib
类别
The translocation t(8;9) generates the fusion gene PCM1-JAK2, leading to continuous activation of JAK2 tyrosine kinase. t(8;9)/PCM1-JAK2 is the most common myelodysplastic/myeloproliferative neoplasm. Patients with this abnormality have similar features and JAK2 kinase inhibitor (ruxolitinib) is an effective treatment. However, the long-term remission results of ruxolitinib are varied, so it is important to determine the response to ruxolitinib. This study describes a patient with eosinophilia-associated myeloproliferative neoplasm with t(8;9)(p21;p24), who has achieved sustained response for >1 year since the administration of ruxolitinib.
The translocation t(8;9) produces the fusion gene PCM1-JAK2, resulting in the continuous activation of the JAK2 tyrosine kinase. Myelodysplastic/myeloproliferative neoplasms are the most common disease with t(8;9)/PCM1-JAK2. Individuals with this abnormality have similar features, and JAK2 kinase inhibitor (ruxolitinib) is an effective treatment of the condition. The long-term remission results of ruxolitinib are varied. It is important to determine the response to ruxolitinib. Here, we describe a patient who has been diagnosed with eosinophilia-associated myeloproliferative neoplasm with t(8;9)(p21;p24). This patient has achieved sustained response for >1 year since the administration of ruxolitinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据